Global Intravenous Immunoglobulin (IVIg) Market Growth 2023-2029

Global Intravenous Immunoglobulin (IVIg) Market Growth 2023-2029

Intravenous Immunoglobulin, also called gamma globulin or antibodies, is a highly purified blood product preparation that is derived from large pools of plasma donors. Plasma from approximately 1,000 to 10,000 persons is present in each unit or “lot” of Intravenous Immunoglobulin.

LPI (LP Information)' newest research report, the “Intravenous Immunoglobulin (IVIg) Industry Forecast” looks at past sales and reviews total world Intravenous Immunoglobulin (IVIg) sales in 2022, providing a comprehensive analysis by region and market sector of projected Intravenous Immunoglobulin (IVIg) sales for 2023 through 2029. With Intravenous Immunoglobulin (IVIg) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Intravenous Immunoglobulin (IVIg) industry.

This Insight Report provides a comprehensive analysis of the global Intravenous Immunoglobulin (IVIg) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Intravenous Immunoglobulin (IVIg) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Intravenous Immunoglobulin (IVIg) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Intravenous Immunoglobulin (IVIg) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Intravenous Immunoglobulin (IVIg).

The global Intravenous Immunoglobulin (IVIg) market size is projected to grow from US$ 10090 million in 2022 to US$ 15290 million in 2029; it is expected to grow at a CAGR of 15290 from 2023 to 2029.

Global Intravenous Immunoglobulin (IVIg) main players are Baxter, Grifols, CSL, Octapharma, etc. Global top four manufacturers hold a share above 65%. North America is the largest market, with a share about 45%.

This report presents a comprehensive overview, market shares, and growth opportunities of Intravenous Immunoglobulin (IVIg) market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
IVIg Liquid
IVIg Powder

Segmentation by application
Immunodeficiency
Autoimmune Disease
Acute Infection

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Baxter
Grifols
CSL
Octapharma
Biotest
Kedrion
Hualan Bio
CNBG
Shanghai RAAS
CBPO
LFB Group
BPL
Sichuan Yuanda Shuyang

Key Questions Addressed in this Report

What is the 10-year outlook for the global Intravenous Immunoglobulin (IVIg) market?

What factors are driving Intravenous Immunoglobulin (IVIg) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Intravenous Immunoglobulin (IVIg) market opportunities vary by end market size?

How does Intravenous Immunoglobulin (IVIg) break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.